Technical Analysis for RYZB - RayzeBio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -0.81% | |
| Hot IPO Pullback | Bullish Swing Setup | -0.81% | |
| New 52 Week Low | Weakness | -0.81% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Inside Day | 3 days ago |
| Gap Down Partially Closed | 3 days ago |
| Gap Down Closed | 3 days ago |
| Reversed from Down | 3 days ago |
| Gap Up Closed | 3 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Treatment Of Cancer Pancreatic Cancer Diagnostic Imaging Hepatology Hepatocellular Carcinoma Neuroendocrine Tumor Neuroendocrinology
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Treatment Of Cancer Pancreatic Cancer Diagnostic Imaging Hepatology Hepatocellular Carcinoma Neuroendocrine Tumor Neuroendocrinology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.0 |
| 52 Week Low | 18.4603 |
| Average Volume | 562,036 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 0.00 |
| Average True Range | 0.00 |
| RSI (14) | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs) | N/A |
| Chandelier Exit (Short, 3 ATRs) | N/A |
| Upper Bollinger Bands | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.73 | ||||
| Resistance 3 (R3) | 21.93 | 21.42 | 21.38 | ||
| Resistance 2 (R2) | 21.42 | 20.89 | 21.32 | 21.26 | |
| Resistance 1 (R1) | 20.52 | 20.56 | 20.27 | 20.32 | 21.14 |
| Pivot Point | 20.02 | 20.02 | 19.89 | 19.92 | 20.02 |
| Support 1 (S1) | 19.12 | 19.48 | 18.87 | 18.92 | 18.10 |
| Support 2 (S2) | 18.61 | 19.15 | 18.51 | 17.98 | |
| Support 3 (S3) | 17.71 | 18.61 | 17.86 | ||
| Support 4 (S4) | 17.51 |
